Ocular

OCUL NASDAQ
4.327
-0.033
-0.75%
Opening 14:34 06/25 EDT
Open
4.270
Prev Close
4.360
High
4.390
Low
4.120
Volume
554.50K
Avg Vol (3M)
763.63K
52 Week High
7.77
52 Week Low
2.350
% Turnover
1.29%
Market Cap
185.36M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Ocular OCUL stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
MORE >

Recently

Name
Price
%Change